View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Merck & Co Inc: 2 directors

Two Directors at Merck & Co Inc sold after exercising options/sold 100,193 shares at between 126.649USD and 126.968USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Moody's assigns A1 rating to Merck's sr. notes; stable outlook

Moody's Investors Service ("Moody's") assigned an A1 rating to the new senior unsecured notes offering of Merck & Co., Inc. ("Merck"). There are no changes to Merck's existing ratings including the A1 senior unsecured long-term rating or the Prime-1 short-term rating. The outlook remains stable. ...

Moody's: Merck's acquisition of Prometheus will strengthen immunology ...

Moody's Investors Service commented that Merck & Co., Inc.'s acquisition of Prometheus Biosciences, Inc. ("Prometheus") for approximately $10.8 billion will enhance Merck's pipeline in immunology. However, the acquisition also entails pipeline and commercial execution risk, given the high price tag....

Merck & Co., Inc.: Merck's acquisition of Prometheus will strengthen i...

The deal has pipeline and commercial execution risk, but Merck's M&A capacity is high

Brian Moretta ... (+4)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
  • Riccardo Bindi

Hardman & Co Monthly: April 2023

Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...

AMGN AMGEN INC.
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S

Merck & Co., Inc.: Update to analysis after outlook change to stable

Our credit view of this issuer reflects its status as a large global pharmaceutical company with solid growth and conservative financial policies, constrained by concentration in Keytruda.

Sid Rajeev
  • Sid Rajeev

Ocean Biomedical Inc. (NASDAQ: OCEA) – An Incubator with Potential Tre...

Fundamental Research Corp has issued a report entitled “An Incubator with Potential Treatments for Cancer, Malaria and Fibrosis – Introductory Note” and dated February 23, 2023. The full report is now at

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Many Indexes and Sectors Testing Resistance Note: This Compass is an abbreviated report. We will resume our normal report layout next week. In our previous Compass (Jan. 24), we discussed our belief that equities were still in the midst of a rally/short squeeze, but that the rally is likely to fizzle in the 4100-4165 area (the top-end of our expected 2023 trading range) on the S&P 500. And, as you will see below, countless other indexes and Sectors are testing important resistance levels. We c...

Merck & Co., Inc.: Update to credit analysis – Keytruda will drive ove...

Our credit view of Merck reflects its leadership in immuno-oncology and its strong earnings growth, tempered by rising concentration in Keytruda and event risk related to acquisitions.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Indexes Form Bear Flag Patterns Within Downtrends We continue to view the price action over the past month as a bear market bounce in the S&P 500, Nasdaq 100 (QQQ), and Russell 2000 (IWM), as each index appears to be forming a bearish flag pattern. Until the S&P 500, QQQ, and IWM can break above their YTD downtrends, we remain bearish, and believe investors should be using rallies to reduce overall exposure in preparation for new lows ahead... see charts below. U.S. Dollar, 10-Yr Treasury Yiel...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Signs of Disinflation? A bear market bounce is underway after the S&P 500, Nasdaq 100 (QQQ), and Russell 2000 (IWM) found support at their respective downtrend channels, a possibility we discussed last week. Still, until the S&P 500, QQQ, and IWM can break above their various downtrends, we remain bearish, and believe investors should be using rallies to reduce overall exposure. Signs of Disinflation? We are starting to see early signs that inflation is peaking, as commodity prices have pulled...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

10-Year Treasury Yield Testing 40-Year Resistance; Upgrading Health Care to Overweight Whether or not the lows for this correction have already been established remains to be seen, but evidence is mounting that suggests a test of the lows, and possibly a break to new lows, is increasingly likely. Regardless, continue to stick with the commodity and defensive Sectors, all of which hit new price and RS highs in recent days. 10-Year Treasury Yield. We have discussed our expectations for rising ra...

MERCK & COMPANY sees an upgrade to Slightly Positive due to a better f...

The general evaluation of MERCK & COMPANY (US), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 18, 2022, the closing price was ...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2021 11 02

Merck's (MRK) flagship Keytruda drug has substantially higher economic moats than the market realizes, and it has the potential to expand its profitability further. Uniform Accounting highlights that the market is missing Keytruda's economic potential, indicating equity upside. In addition to its solid portfolio of cash cow drugs, Merck's flagship biologic drug, Keytruda, has accelerated the company's earnings potential, helping grow Uniform ROA from 11% to 15%, and a forecast rise to 18%. As i...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch